Certara (NASDAQ:CERT) Given New $12.00 Price Target at Barclays

Certara (NASDAQ:CERT - Get Free Report) had its price target dropped by equities researchers at Barclays from $14.00 to $12.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Barclays's price target would suggest a potential upside of 9.19% from the stock's previous close.

Several other research analysts also recently weighed in on the stock. KeyCorp lowered their price objective on shares of Certara from $23.00 to $20.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. JMP Securities restated a "market perform" rating on shares of Certara in a report on Wednesday, July 10th. Robert W. Baird lowered their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday. Finally, UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $15.92.

Certara Stock Up 0.7 %

NASDAQ:CERT traded up $0.08 during mid-day trading on Thursday, hitting $10.99. 1,935,541 shares of the company's stock were exchanged, compared to its average volume of 785,062. The company has a 50 day simple moving average of $11.07 and a 200-day simple moving average of $13.75. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. Certara has a fifty-two week low of $9.99 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business's revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, analysts expect that Certara will post 0.27 earnings per share for the current year.

Insider Activity at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company's stock, valued at $1,125,658.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new position in Certara during the third quarter worth about $367,000. Zions Bancorporation N.A. boosted its position in shares of Certara by 18.5% in the third quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company's stock valued at $899,000 after acquiring an additional 11,995 shares during the period. KBC Group NV boosted its position in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after acquiring an additional 1,584 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Certara by 6.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company's stock valued at $2,473,000 after acquiring an additional 13,500 shares during the period. Finally, Geneva Capital Management LLC boosted its position in shares of Certara by 0.7% in the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company's stock valued at $64,525,000 after acquiring an additional 37,392 shares during the period. Institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.